QT Imaging Holdings Delivers Its Breast Imaging Scanner to Innovative Radiology in Des Moines, Iowa
NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (OTCQB:QTIH) a medical device company engaged in research, development, and commercialization of innovative body imaging systems is proud to announce the delivery and installation of its QT Imaging Breast Acoustic CT™ Scanner at Innovative Radiology, led by Dr. John Tentinger in Des Moines, Iowa.
This installation brings QT Imaging's radiation-free, 3D breast imaging technology to patients in Iowa for the first time. QT Imaging's breast imaging scanner uses proprietary low-frequency ultrasound to generate high-resolution, 3D images of breast tissue—without ionizing radiation or compression. This non-invasive approach provides a safer, more comfortable, high resolution, and repeatable imaging option, particularly for patients with dense breast tissue.
'We are excited to bring our breast imaging technology to Des Moines and to partner with Dr. Tentinger and Innovative Radiology,' said Dr. Raluca Dinu, CEO of QT Imaging Holdings. 'This collaboration reflects our shared vision of advancing women's health by making high-quality, patient-friendly imaging more accessible. We're also grateful to our distribution partner, NXC Imaging, for facilitating this important connection and supporting the successful deployment of our technology.'
Dr. Tentinger, a respected board-certified radiologist, leads Innovative Radiology with a focus on furthering access to precise imaging and accurate diagnostic assessments to ensure that patients have a clear road map to optimally navigate their health journey. In addition to the newly installed QT Imaging Breast Acoustic CT Scanner, his facility is equipped with a full suite of imaging technologies, including mammography, MRI, CT, ultrasound, and X-ray—ensuring comprehensive diagnostic capabilities under one roof. The addition of QTI's technology further enhances the clinic's commitment to offering the latest in imaging innovation.
'Our practice is dedicated to improving diagnostic outcomes while prioritizing patient experience,' said Dr. Tentinger. 'The QT Imaging Breast Acoustic CT Scanner allows us to offer a safer, gentler, yet highly detailed breast imaging option that many patients will prefer. We're proud to be the first in Iowa to offer this technology.'
About QT Imaging Holdings, Inc.
QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient's experience. For more information on QT Imaging Holdings, Inc., please visit the company's website at www.qtimaging.com.
Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.
About Innovative Radiology, Inc.
Innovative Radiology specializes in precision imaging to optimize patient outcomes. Utilizing state-of-the-art imaging equipment, it employs highly skilled radiologists and technologists who provide detailed and timely diagnostic assessments for medical providers, so they are empowered to make confident healthcare decisions for their patients.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as 'will,' and 'expect,' or the negative thereof or comparable terminology, and include (without limitation) statements regarding the presentation and performance of the QT Imaging Breast Acoustic CT imaging technology, plans for QT Imaging Holdings, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and 'bring to market' plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading 'Risk Factors' and in other sections of QT Imaging Holding's filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Investors in Marchex (NASDAQ:MCHX) have seen decent returns of 36% over the past three years
Low-cost index funds make it easy to achieve average market returns. But in any diversified portfolio of stocks, you'll see some that fall short of the average. Unfortunately for shareholders, while the Marchex, Inc. (NASDAQ:MCHX) share price is up 36% in the last three years, that falls short of the market return. Looking at more recent returns, the stock is up 19% in a year. Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Marchex wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally hope to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. Marchex actually saw its revenue drop by 3.9% per year over three years. The modest share price gain of 11% per year suggests holders are sanguine about the falling revenue. As a general rule we don't like it when a loss-making company isn't even growing revenue. You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values). We consider it positive that insiders have made significant purchases in the last year. Even so, future earnings will be far more important to whether current shareholders make money. You can see what analysts are predicting for Marchex in this interactive graph of future profit estimates. It's nice to see that Marchex shareholders have received a total shareholder return of 19% over the last year. That's better than the annualised return of 3% over half a decade, implying that the company is doing better recently. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. It's always interesting to track share price performance over the longer term. But to understand Marchex better, we need to consider many other factors. Take risks, for example - Marchex has 1 warning sign we think you should be aware of. Marchex is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
2 hours ago
- Yahoo
Is It Too Late To Consider Buying Extreme Networks, Inc. (NASDAQ:EXTR)?
Extreme Networks, Inc. (NASDAQ:EXTR), might not be a large cap stock, but it received a lot of attention from a substantial price increase on the NASDAQGS over the last few months. Shareholders may appreciate the recent price jump, but the company still has a way to go before reaching its yearly highs again. As a mid-cap stock with high coverage by analysts, you could assume any recent changes in the company's outlook is already priced into the stock. However, what if the stock is still a bargain? Let's take a look at Extreme Networks's outlook and value based on the most recent financial data to see if the opportunity still exists. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Good news, investors! Extreme Networks is still a bargain right now. According to our valuation, the intrinsic value for the stock is $24.12, but it is currently trading at US$16.08 on the share market, meaning that there is still an opportunity to buy now. However, given that Extreme Networks's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility. Check out our latest analysis for Extreme Networks Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. With revenues expected to grow by 33% over the next couple of years, the future seems bright for Extreme Networks. If the level of expenses is able to be maintained, it looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation. Are you a shareholder? Since EXTR is currently undervalued, it may be a great time to increase your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current undervaluation. Are you a potential investor? If you've been keeping an eye on EXTR for a while, now might be the time to enter the stock. Its buoyant future outlook isn't fully reflected in the current share price yet, which means it's not too late to buy EXTR. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed investment decision. It can be quite valuable to consider what analysts expect for Extreme Networks from their most recent forecasts. Luckily, you can check out what analysts are forecasting by clicking here. If you are no longer interested in Extreme Networks, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
2 hours ago
- Business Upturn
FTRE SHAREHOLDERS: Fortrea Holdings Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by August 1 Deadline (NASDAQ:FTRE)
NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting Investors have until August 1, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Fortrea securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Deslande v. Fortrea Holdings Inc., et al. , No. 1:25-cv-04630. Why was Fortrea Sued for Securities Fraud? Fortrea is a global contract research organization that provides biopharmaceutical product and medical device development solutions. In June 2023, Fortrea was spun off into a standalone, publicly traded company by Labcorp Holdings Inc. ('Labcorp'). In connection with the spin-off, Fortrea entered into several transition services agreements (the 'TSAs'), pursuant to which it agreed to pay Labcorp for certain transitional services over a set period. As alleged, Fortrea discussed the significant cost savings and margin improvements that would result from exiting the TSAs. In truth, Fortrea overstated the cost savings and margin improvement it would achieve by exiting the TSAs, as well as the amount of revenue it would generate from pre-spin projects. The Stock Declines as the Truth is Revealed On September 25, 2024, investment bank Jefferies published a report stating that the cost savings Fortrea would achieve from exiting the TSAs were '[n]ot as [m]aterial as [o]ne [m]ight [t]hink.' On this news, the price of Fortrea stock declined $2.73 per share, or over 12%, from a closing price of $22.21 per share on September 24, 2024, to $19.48 per share on September 25, 2024. Then, on March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 financial results, revealing that the company's pre-spin projects 'have less revenue and less profitability than expected for 2025' and that 'post-spin work is not coming on fast enough to offset the pre-spin contract economics.' On this news, the price of Fortrea stock declined $3.47 per share, or over 25%, from a closing price of $13.85 per share on February 28, 2025, to $10.38 per share on March 3, 2025, the next trading day. Click here if you suffered losses: What Can You Do? If you invested in Fortrea you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
